Epstein Secrets

research. She launched marketing and outreach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased c

reach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased clinical trials by 40% and grew patient

arch capabilities. e Attracted ongoing contracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. e Grew research revenue by increasing clinical trials by 40%

ontracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. e Grew research revenue by increasing clinical trials by 40% and patient enrollment by over 320% ann

close). And now Novartis & GSK have announced a major series of transactions: creating new consumer-health venture (GSK 63.5% controlling interest), Novartis agrees to buy GSK's oncology unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit to El

t Animal Health to Lilly for $5.4B (NOVN VX +2.3%, GSK LN +5.3%, LLY no volume) • Astrazeneca ADR's closed +8.8% yesterday on Sunday Times story of Pfizer talks (trading +6.9%) • Philips misses estimates, adjusted EBITA 12% light on HC + lighting, weaker EM & FX (trading -7.0%) • Accor O1 sales miss

bserver), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Sci

Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region, and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories.